Boehringer Ingelheim announced the grand opening of its newly expanded research and development facility in Athens, Georgia. As the largest animal health company in Georgia, this Boehringer ...
The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard ...
AllianceQUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery 24.10.2024 / 09:30 CET/CESTThe issuer is solely responsible for the content of this ...
It’s important to maintain a temperature of 77 degrees or cooler, and above freezing, so efficacy is highest when the product ...
Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...
Asthma affects approximately 262 million people globally, with the number of asthma incidents having increased by around 15% ...
Bayer and Boehringer Ingelheim both had new data on their HER2-targeting small-molecule drugs to present at the World Conference on Lung Cancer (WCLC), hoping to add new oral therapies to the ...
Pediatric Orphan Drug Market is Segmented by Type (Oncology, Pulmonary, Neurology, Hematology, Endocrinology, Cardio-vascular, Metabolic Disorders), by Application (0-1 Years, 1-3 Years, 3-6 Years, ...
Boehringer Ingelheim has taken an option on a family ... Sosei Heptares is a specialist in drugs that target G-protein coupled receptors (GPCRs), a fertile source of drug targets for the pharma ...
The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by ...
The Progressive Fibrosing Interstitial Lung Disease (PF-ILD) market is currently valued at USD 4,742.2 Million in 2023 and is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback